1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2017, Issue 2
  5. Article
Volume 2017, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

While few international studies have assessed the association between omeprazole use and the risk of infection (CDI), research into this is lacking in Saudi Arabia and the Middle East region. The aim of this study was to determine whether exposure to omeprazole is associated with the risk of infection in a sample of hospitalized Saudi patients. A retrospective matched case–control study was conducted at the King Abdulaziz Medical City in Riyadh, Saudi Arabia, from 1 August 2010 through 31 July 2015. The analysis included a total of 200 patients: 100 CDI cases and 100 matched controls. The majority (60%, 120 out of 200) of patients had received proton pump inhibitors (PPIs), and a minority (18.5%, 37 out of 200) had received omeprazole. The PPI use was insignificantly higher in CDI cases than in controls. However, the use of omeprazole was significantly higher in CDI cases compared with controls. Specifically, patients receiving omeprazole were two times more likely to develop CDI compared with controls (aOR = 2.1, 95% confidence interval (CI) = (1.007–4.437)). After adjusting for potential predictors of CDI, watery diarrhea (aOR = 59.1, 95% CI = 19.831–175.974) and abdominal pain (aOR = 7.5, 95% CI = 2.184–25.445) were found to be independent predictors of CDI. The data suggests that PPIs were commonly used in patients admitted to King Abdulaziz Medical City in Riyadh: six out of ten patients received PPIs. The findings support a possible association between the use of omeprazole and a high risk of CDI. To confirm causality, the link between omeprazole and CDI should be assessed in a large interventional study.

© 2017 Al Otaibi, Ahmed, Alammari, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2017.2
2017-07-24
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2017/2/qmj.2017.2.html?itemId=/content/journals/10.5339/qmj.2017.2&mimeType=html&fmt=ahah

References

  1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009; 7:7:526–536.
     [Google Scholar]
  2. Bauer MP, Notermans DW, Van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al.  Clostridium difficile infection in Europe: A hospital-based survey. The Lancet. 2011; 377:9759:63–73.
     [Google Scholar]
  3. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353:23:2442–2449.
     [Google Scholar]
  4. McDonald LC, Killgore GE, Thompson A, Owens Jr RC, Kazakova SV, Sambol SP, et al.  An epidemic, toxin gene-variant strain of Clostridium difficile . N Engl J Med. 2005; 353:23:2433–2441.
     [Google Scholar]
  5. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case–control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008; 62:2:388–396.
     [Google Scholar]
  6. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: A population-based study. Clin Infect Dis. 2006; 43:10:1272–1276.
     [Google Scholar]
  7. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case–control studies. Can Med Assoc J. 2004; 171:1:33–38.
     [Google Scholar]
  8. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008; 103:9:2308–2313.
     [Google Scholar]
  9. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003; 54:3:243–245.
     [Google Scholar]
  10. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroenter. 2012; 107:7:1001–1010.
     [Google Scholar]
  11. Abramowitz J, Thakkar P, Isa A, Truong A, Park C, Rosenfeld RM. Adverse event reporting for proton pump inhibitor therapy: An overview of systematic reviews. Otolaryngol Head Neck Surg. 2016; 155:4:547–554.
     [Google Scholar]
  12. Roughead EE, Chan EW, Choi NK, Griffiths J, Jin XM, Lee J, et al.  Proton pump inhibitors and risk of Clostridium difficile infection: A multi-country study using sequence symmetry analysis. Expert Opin Drug Saf. 2016; 15:12:1589–1595.
     [Google Scholar]
  13. Thipmontree W, Kiratisin P, Manatsathit S, Thamlikitkul V. Epidemiology of suspected Clostridium difficile-associated hospital-acquired diarrhea in hospitalized patients at Siriraj Hospital. J Med Assoc Thai. 2011; 94:Suppl 1:S207–S216.
     [Google Scholar]
  14. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: Key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005; 6:2:105–108.
     [Google Scholar]
  15. Tleyjeh IM, Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al.  Association between proton pump inhibitor therapy and Clostridium difficile infection: A contemporary systematic review and meta-analysis. PLoS ONE. 2012; 7:12:e50836.
     [Google Scholar]
  16. Naggie S, Miller BA, Zuzak KB, Pence BW, Mayo AJ, Nicholson BP, et al.  A case-control study of community-associated Clostridium difficile infection: No role for proton pump inhibitors. Am J Med. 2011; 124:3:276–2e1.
     [Google Scholar]
  17. Debast SB, Vaessen N, Choudry A, Wiegers-Ligtvoet EA, Van Den Berg RJ, Kuijper EJ. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect. 2009; 15:5:427–434.
     [Google Scholar]
  18. Tleyjeh IM, Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al.  Association between proton pump inhibitor therapy and Clostridium difficile infection: A contemporary systematic review and meta-analysis. PLoS ONE. 2012; 7:12:e50836.
     [Google Scholar]
  19. Nath SK, Salama S, Persaud D, Thornley JH, Smith I, Foster G, et al.  Drug risk factors associated with a sustained outbreak of Clostridium difficile diarrhea in a teaching hospital. Can J Infect Dis Med Microbiol. 1994; 5:6:270–275.
     [Google Scholar]
  20. Hegarty JP, Sangster W, Harris LR, Stewart DB. Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection. Surgery. 2014; 156:4:972–978.
     [Google Scholar]
  21. Pupaibool J, Khantipong M, Suankratay C. A study of Clostridium difficile-associated disease at King Chulalongkorn Memorial Hospital, Thailand. J Med Assoc Thai. 2008; 91:1:37–43.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2017.2
Loading
Association between omeprazole use and Clostridium difficile infection among hospitalized patients: A case–control study of the Saudi population
Qatar Medical Journal 2017, 2 (2017); https://doi.org/10.5339/qmj.2017.2
/content/journals/10.5339/qmj.2017.2
/content/journals/10.5339/qmj.2017.2
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): abdominal pain, Clostridium difficile infection, omeprazole, Saudi Arabia and watery diarrhea

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error